Related references
Note: Only part of the references are listed.Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy
Alexandr V. Bazhin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments anc parallelisms with other tissues
Eva Van Overmeire et al.
FRONTIERS IN IMMUNOLOGY (2014)
The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays
Nilanjana Tewari et al.
BMC CANCER (2013)
Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions
Amedeo Amedei et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
Hidekazu Kameshima et al.
CANCER SCIENCE (2013)
Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer
Paola Cappello et al.
GASTROENTEROLOGY (2013)
Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma
Lei Zheng et al.
GASTROENTEROLOGY (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Improvement of surgical results for pancreatic cancer
Werner Hartwig et al.
LANCET ONCOLOGY (2013)
Basic principles of tumor-associated regulatory T cell biology
Peter A. Savage et al.
TRENDS IN IMMUNOLOGY (2013)
What Is Recent in Pancreatic Cancer Immunotherapy?
Elena Niccolai et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Immunotherapy updates in pancreatic cancer: are we there yet?
Krishna Soujanya Gunturu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
What We Have Learned About Pancreatic Cancer From Mouse Models
Pedro A. Perez-Mancera et al.
GASTROENTEROLOGY (2012)
The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma
Ling Xie et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas
Marcherie Davis et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Circulating Myeloid Dendritic Cells as Prognostic Factors in Patients with Pancreatic Cancer Who Have Undergone Surgical Resection
Tomohisa Yamamoto et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer
Tomohisa Yamamoto et al.
PANCREAS (2012)
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
Yukino Kimura et al.
PANCREAS (2012)
An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer
Andrew D. Gilliam et al.
PANCREAS (2012)
Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling
Shumei Song et al.
PLOS ONE (2012)
Cancer-related inflammation: Common themes and therapeutic opportunities
Frances R. Balkwill et al.
SEMINARS IN CANCER BIOLOGY (2012)
Differentiation and gene expression profile of tumor-associated macrophages
Astrid Schmieder et al.
SEMINARS IN CANCER BIOLOGY (2012)
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Ghassan K. Abou-Alfa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
Eric Lutz et al.
ANNALS OF SURGERY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F. Gabitass et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
α-enolase: a promising therapeutic and diagnostic tumor target
Michela Capello et al.
FEBS JOURNAL (2011)
A novel high-affinity human monoclonal antibody to mesothelin
Mitchell Ho et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
Lucia De Monte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Circulating Autoantibodies to Phosphorylated alpha-Enolase are a Hallmark of Pancreatic Cancer
Barbara Tomaino et al.
JOURNAL OF PROTEOME RESEARCH (2011)
The CD40-CD154 Interaction Would Correlate with Proliferation and Immune Escape in Pancreatic Ductal Adenocarcinoma
Yasuhito Shoji et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
Hiroshi Kurahara et al.
JOURNAL OF SURGICAL RESEARCH (2011)
Advances in the assessment and control of the effector functions of therapeutic antibodies
Xu-Rong Jiang et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer
Xiaohui Duan et al.
MEDICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
C. Larbouret et al.
ANNALS OF ONCOLOGY (2010)
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2010)
Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions
Shigeo Koido et al.
CLINICAL IMMUNOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Valerie Dardalhon et al.
JOURNAL OF IMMUNOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
Johan Soderlund et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor
Vegard Tjomsland et al.
PLOS ONE (2010)
Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas
Xiao-Na Fan et al.
PATHOLOGY RESEARCH AND PRACTICE (2010)
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer
Martin Loos et al.
BMC CANCER (2009)
Clinical importance of B7-H3 expression in human pancreatic cancer
I. Yamato et al.
BRITISH JOURNAL OF CANCER (2009)
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer
Fabian Mc. Johnston et al.
CLINICAL CANCER RESEARCH (2009)
Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
S. Mocellin et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome
Caroline J. Voskens et al.
CURRENT MOLECULAR MEDICINE (2009)
Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma
Fei Zhao et al.
IMMUNOLOGY (2009)
An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen
Paola Cappello et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
Yang Feng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Releasable PEGylation of proteins with customized linkers
David Fipula et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma
Jun Chul Chung et al.
ANZ JOURNAL OF SURGERY (2008)
Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients
Ingegerd Hellstrom et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Tumor-associated galectin-3 modulates the function of tumor-reactive T cells
Weiyi Peng et al.
CANCER RESEARCH (2008)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
Peptide-based vaccines for cancer: realizing their potential
Shreya Kanodia et al.
EXPERT REVIEW OF VACCINES (2008)
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
Lei Geng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients
Elena Tassi et al.
JOURNAL OF IMMUNOLOGY (2008)
Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu
Graziella Pratesi et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer
Sebastian Hinz et al.
CANCER RESEARCH (2007)
Design and development of synthetic peptide vaccines: past, present and future
Martijn S. Bijker et al.
EXPERT REVIEW OF VACCINES (2007)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
Robert G. Maki et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
More than one reason to rethink the use of peptides in vaccine design
Anthony W. Purcell et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Preclinical and clinical studies of recombinant poxvirus Vaccines for carcinoma therapy
Philip M. Arlen et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2007)
Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines
H. Pandha et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients
Tetsuya Ikemoto et al.
PANCREAS (2006)
PankoMab:: a potent new generation anti-tumour MUC1 antibody
Antje Danielczyk et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells
Francesca Fallarino et al.
JOURNAL OF IMMUNOLOGY (2006)
Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
G Bellone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells
Hideaki Tsutsumida et al.
CLINICAL CANCER RESEARCH (2006)
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
U Graeven et al.
BRITISH JOURNAL OF CANCER (2006)
Prospects for vaccine therapy for pancreatic cancer
G Gaudernack
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2006)
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer
B Kubuschok et al.
CLINICAL CANCER RESEARCH (2006)
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8(+) T cells by dendritic cells loaded with killed allogeneic breast cancer cells
Hiroaki Saito et al.
BREAST CANCER RESEARCH (2006)
High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients
FH Schmitz-Winnenthal et al.
CANCER RESEARCH (2005)
Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells
S Koido et al.
CLINICAL CANCER RESEARCH (2005)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II - study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]
R Krempien et al.
BMC CANCER (2005)
Ductal neoplasia of the pancreas: Nosologic, clinicopathologic, and biologic aspects
NV Adsay et al.
SEMINARS IN RADIATION ONCOLOGY (2005)
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients
M Ho et al.
CLINICAL CANCER RESEARCH (2005)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft
RD Blumenthal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth
C Bangard et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
MUC1 and MUC2 in pancreatic neoplasia
E Levi et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
DV Gold et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate
CF Qu et al.
BRITISH JOURNAL OF CANCER (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
CD8(+) tumor-infiltrating lymphocytes together with CD4(+) tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma
A Fukunaga et al.
PANCREAS (2004)
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma
I Esposito et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Potential prophylactic measures against postoperative immunosuppression: Could they reduce recurrence rates in oncological patients?
G Shakhar et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis
AJ Karayiannakis et al.
CANCER LETTERS (2003)
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Y Hamanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines
HJ Monstein et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
EM Jaffee et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production
H Weighardt et al.
SURGERY (2000)
Share Paper
